Aim of the study is to investigate if adjuvant immunoadsorption is superior to standard immunosuppressive treatment in inducing clinical remission in pemphigus.
Sponsor: Philipps-University Marburg
SEEK ID: https://ldh.kks-marburg.imise.uni-leipzig.de/projects/4
Funding codes:- DFG
Public web page: Not specified
NFDI4Health PIs: No PIs for this Trial Project
Trial Project start date: 7th Mar 2011
Trial Project end date: 9th Mar 2015
- : Study
- : Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus
- : English
- : IA-pem
- : English
- : Aim of the study is to investigate if adjuvant immunoadsorption is superior to standard immunosuppressive treatment in inducing clinical remission in pemphigus.
- : English
- : adjuvant immunoadsorption
- : immunosuppressive treatment
- : pemphigus
- : Organisational
- Details about the contributing organisation(s)/institution(s)/group(s)
- : Sponsor (primary)
- : SCHM 1686/3-2
- : Philipps-University Marburg
- Details about the contributing person(s)
- : Not specified
- : Not specified
- : Not specified
- Digital identifier(s)
- : Not specified
- : Not specified
- : info@kks.uni-marburg.de
- : Not specified
- Organisation(s) associated with the contributor
- : Philipps-University Marburg/KKS
- : Karl-von-Frisch-Str. 4, 35043 Marburg
- : https://www.kks.uni-marburg.de
- Digital identifier(s)
- : Not specified
- : Not specified
- : DRKS
- : DRKS00000566
- : Interventional
- Specification of the type of the Project
- : Parallel
- : []
- Primary health condition(s) or disease(s) considered in the Project
- : Pemphigus vulgaris
- : ICD-10
- : Not specified
- Groups of diseases or conditions(*)
- : Diseases of the skin and subcutaneous tissue (XII)
- : []
- : Not specified
- Administrative information about the Project
- : Request for approval submitted, approval granted
- : Completed: Recruitment, data collection, and data quality management completed normally
- : No
- : 7 March 2011
- : 9 March 2015
- : Multicentric
- : 26
- : Not specified
- : Not specified
- : Person
- Eligibility criteria for Project participants
- Eligibility criteria: Minimum age
- : 18
- : Years
- Eligibility criteria: Maximum age
- : 99
- : Years
- : Male, Female
- : see protocol
- : see protocol
- Population of the Project(*)
- : International
- : Germany
- : Germany - nationwide; Austria - nationwide
- Interventions of the Project
- : Immunoadsorption on four consecutive days (= 1 treatment cycle) using Immunosorba® (Fresenius Medical Care)
- : Drug (including placebo)
- : Not specified
- : Experimental
- Exposures of the Project
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- Outcome measures in the Project
- : Time to clinical remission
- : Not specified
- : Primary
- : Not specified
- : Not specified
- : []
- Data sharing strategy of the Project(*)
- : Undecided, it is not yet known if data will be made available
- : []
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- Non-interventional aspects of the Project
- : []
- Target follow-up duration of the Project
- : Not specified
- : Not specified
- : Not specified
- : []
- : Not specified
- Interventional aspects of the Project
- : Not applicable
- Masking of intervention(s) assignment
- : false
- : []
- : Not specified
- : Randomized
- : Not specified
Related items
Trial Projects:
- Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION)
- Lymphadenectomy in Ovarian Neoplasms (LION)
- Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-pem)
- A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
- Efficacy and Safety of Pegylated-Proline-Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients with Chronic Myeloid Leukemia (CML) who Discontinue ABL-Kinase Inhibitor Therapy
- A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA
Institutions: Philipps-University Marburg, Coordinating Center for Clinical Trials

Trial Projects:
- Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION)
- Lymphadenectomy in Ovarian Neoplasms (LION)
- Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-pem)
- A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA
- A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
- Efficacy and Safety of Pegylated-Proline-Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients with Chronic Myeloid Leukemia (CML) who Discontinue ABL-Kinase Inhibitor Therapy
Web page: Not specified
Abstract (Expand)
Authors: N. van Beek, R. Eming, A. Reuss, D. Zillikens, M. Sardy, C. Gunther, D. Kiritsi, S. Benoit, S. Beissert, R. Glaser, H. Gollnick, O. N. Horvath, C. Pfeiffer, M. Rocken, F. Schauer, S. Schreml, K. Steinbrink, A. Zink, C. Schade-Brittinger, M. Hertl, E. Schmidt
Date Published: 17th Apr 2024
Publication Type: Journal
PubMed ID: 38133541
Citation: Br J Dermatol. 2024 Apr 17;190(5):657-667. doi: 10.1093/bjd/ljad489.
Creator: Gerrit zur Hausen
Submitter: Gerrit zur Hausen